Radisens and Beckman Coulter sign Collaborative Development and Evaluation Agreement
Cork, Ireland – May 29, 2012 – Radisens Diagnostics and Beckman Coulter, Inc. have announced that they have entered into a Collaborative Development and Evaluation Agreement to exploit Radisens Diagnostics’ proprietary platform technology for cellular analysis applications.
Comprising part of Radisens point-of-care diagnostic platform, the proprietary digital HDR™ detection engine delivers industry leading multi-colour fluorescence and scattering sensitivity. This matchbox-sized HDR™ detection engine delivers a step-change in the market for portable multi-fluorescent flow cytometers, cell analysers and diagnostic devices. The six decades of optical dynamic range enables truly automatic sample-to-answer operation, with the digital solid-state technology removing the need for expensive maintenance cycles, while significantly reducing instrument cost.
Jerry O’Brien, CEO of Radisens Diagnostics said, “This strategic collaboration with Beckman Coulter demonstrates the disruptive nature of the diagnostics technology that we are developing at Radisens in terms of performance, cost and usability. This opens up huge growth opportunities in providing clinicians and researchers a powerful, low-cost diagnostic tool onto their desk with the advanced laboratory performance they require.”
Commenting on the deal, Mario Koksch, Director Product Management for Flow Cytometry at Beckman Coulter, Inc., said “We are very excited by the potential performance, cost and usability benefits that Radisens can bring with its proprietary HDR™ detection technology. We look forward to realizing the huge potential this offers within emerging high-growth flow cytometry markets, while maintaining a reputation for high performance.”
About Radisens Diagnostics
Radisens Diagnostics, a venture-backed diagnostics company, is breaking new ground in the decentralization of routine blood testing from central reference laboratories into physician offices, outpatient clinics, hospital bedsides and other point-of-care settings. With a finger-prick of blood, this multi-mode diagnostic device will return laboratory-grade results within minutes during a patient’s physician visit.
Radisens’ applications at launch in 2015 will concentrate on test panels to provide clinical benefits for more efficient chronic disease management. A single sample-to-result analyzer, this IP protected platform will provide a step improvement in blood test performance, and will remove the many anxious days or weeks of waiting for routine blood test results, provide better patient outcomes and introduce much needed efficiencies into healthcare systems worldwide.
About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, CA, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 275,000 Beckman Coulter systems operate in both diagnostics and life sciences laboratories on six continents. For more than 75 years, Beckman Coulter products have been making a difference in peoples’ lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and reducing the cost of care. For more information, visit www.beckmancoulter.com.
Radisens Diagnostics Ltd.
E: info (at) radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909